FENC - フェネック・ファ―マシュ―ティカルズ （Fennec Pharmaceuticals Inc.） フェネック・ファ―マシュ―ティカルズFENCのチャート
FENCの企業情報
| symbol | FENC |
|---|---|
| 会社名 | Fennec Pharmaceuticals Inc （フェネック・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 フェネック・ファーマシューティカルス(Fennec Pharmaceuticals Inc.)( 旧名：Adherex Technologies Inc.)はガンの治療法に焦点を当てる生物薬剤会社である。同社のリード製品は、臨床開発段階にある、チオ硫酸ナトリウム(STS)とエニルウラシルを含む。STSは、子供のシスプラチン難聴或いは耳毒性の予防のための第Ⅲ相臨床試験にある化学還元剤とする水溶性チオール化合物である。エニルウラシルは、ジヒドロピリミジン・デヒドロゲナーゼ(DPD)の不可逆阻害剤であり、主に体内で5-FUの急速な分解に関与する酵素である。 フェネック・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、主にがん治療用の医薬品の開発に従事する。チオ硫酸ナトリウムは抗がん剤のシスプラチン誘発性難聴の予防に使用、エニルウラシルは経口薬で転移性乳がんの治療に使用される。本社所在地はノ―スカロライナ州リサ―チ・トライアングル・パ―ク。 Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation in the U.S. for this potential use. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans. |
| 本社所在地 | P.O. Box 13628 68 T.W. Alexander Drive Research Triangle Park NC 27709 USA |
| 代表者氏名 | Khalid Islam ハリドイスラム |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 919-636-4530 |
| 設立年月日 | 36039 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 3人 |
| url | www.adherex.com |
| nasdaq_url | https://www.nasdaq.com/symbol/fenc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -9.15700 |
| 終値（lastsale） | 7.89 |
| 時価総額（marketcap） | 148284391.74 |
| 時価総額 | 時価総額（百万ドル） 147.15680 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 121.51680 |
| 当期純利益 | 当期純利益（百万ドル） -8.79700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Fennec Pharmaceuticals Inc revenues was not reported. Net loss increased 73% to $4.2M. Higher net loss reflects General and administrative increase of 75% to $3M (expense) Research and development increase from $558K to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.17 to -$0.22. |
FENCのテクニカル分析
FENCのニュース
Fennec Pharmaceuticals: Undervalued, Near-Cash-Flow-Positive, Possible Buyout Candidate 2023/04/26 12:33:16 Seeking Alpha
After a long approval process, with two CRL speed bumps, Fennec is finally a de-risked investment opportunity with substantial upside potential. Read more here.
HC Wainwright Research Analysts Lower Earnings Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC) 2023/04/06 06:00:42 The AM Reporter
Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) – Analysts at HC Wainwright dropped their FY2024 earnings per share estimates for shares of Fennec Pharmaceuticals in a research note issued to investors on Tuesday, April 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.49 per share for the year, down from […]
Fennec Pharmaceuticals Gains Momentum With Industry Endorsements 2023/04/05 12:43:01 Seeking Alpha
Fennec received FDA approval for Pedmark. The NCCN and the EMA have endorsed Pedmark, strengthening its market prospects. Read more on FENC stock here.
Fennec Pharmaceuticals (NASDAQ:FENC) Rating Reiterated by HC Wainwright 2023/04/02 08:36:41 The AM Reporter
Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 116.35% from the stock’s […]
Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients 2023/03/31 12:03:00 Wallstreet:Online
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~ ~ Positive CHMP Opinion Based on Clinical Results Demonstrating Prevention of Ototoxicity and a Favorable Benefit-Risk Profile With Pedmarqsi~ ~ Pedmarqsi is Currently Marketed as PEDMARK in
Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow (NASDAQ:FENC) 2022/11/23 16:33:59 Seeking Alpha
The following slide deck was published by Fennec Pharmaceuticals Inc.
FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE | MarketScreener 2022/11/14 15:00:33 MarketScreener
Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company focused on the development of PEDMARK to reduce the risk of ototoxicity associated with cisplatin in pediatric… | November 14, 2022
Fennec Pharmaceuticals GAAP EPS of -$0.31 misses by $0.13 (NASDAQ:FENC) 2022/11/11 12:16:13 Seeking Alpha
Fennec Pharmaceuticals press release (FENC): Q3 GAAP EPS of -$0.31 misses by $0.13.Cash and cash equivalents of $29.75M.“This was an important quarter for Fennec with the FDA approval…
Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update 2022/11/11 12:10:00 GlobeNewswire
~ In September 2022, FDA Approved PEDMARK ® , the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~
Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States 2022/10/17 12:00:00 GlobeNewswire
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~
Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update 2022/05/12 10:00:00 GlobeNewswire
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~
U.S. FDA accepts Fennec Pharma''s New Drug Application (NDA) Resubmission for PEDMARK 2022/04/27 12:39:53 Benzinga
Fennec Pharmaceuticals Inc. (NASDAQ: FENC ) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing of resubmitted New Drug Application (NDA) for PEDMARK TM (sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients one month to less than 18 years of age with localized, non-metastatic, solid tumors. The … Full story available on Benzinga.com
Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK 2022/04/27 10:00:00 Wallstreet:Online
~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM